Two leading organisations have begun discussions about starting a clinical study to evaluate the response of bladder cancer patients to BCG immunotherapy.
Ludwig Enterprises, which is an innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, has entered into discussions with Emerson Urology Associates about the study.
Bladder cancer is the ninth most common cancer worldwide.
Cisplatin-based chemotherapy followed by surgical removal of the bladder or radiation therapy and concomitant chemotherapy is the standard treatment for bladder cancer that has invaded muscle tissue.
An additional approach is immunotherapy and BCG is a cancer vaccine that uses weakened bacteria to stimulate the immune system.
Ludwig Enterprises and Emerson Urology Associates aim to use Ludgwig’s proprietary genetic inflammatory markers to study patients with early-stage superficial bladder cancer and assess their therapeutic response to BCG immunotherapy.
It is hoped the study will lead to the creation of a predictive model of early-stage cancer occurrence at a presymptomatic stage and show which patients will respond to specific anticancer chemotherapy.
